|
|
|
|
Echinacea Preparation as Effective as Tamiflu® in Early Flu Cases in Large Clinical Trial
(AUSTIN, Texas, June 17, 2015) New
clinical research suggests that an herbal medicinal product containing a
proprietary combination of a concentrated echinacea herb and root extract is as
effective as the conventional antiviral medicine oseltamivir (Tamiflu®)
in the early treatment of influenza. The results of the randomized, double-blind,
controlled clinical trial were published online in April in the open-access journal Current
Therapeutic Research. [1]
For the study, researchers recruited 473 patients who had exhibited flu
symptoms for less than 48 hours from 29 primary care practices in the Czech
Republic. The patients were randomly assigned to take Echinaforce®
Hotdrink syrup, a beverage containing an alcoholic extract prepared from
freshly harvested echinacea (Echinacea purpurea) herb
and root (95% herb; 5% root) supplemented with European elderberry (Sambucus
nigra), for 10 days, or oseltamivir for five days followed by
placebo for five days. (Echinaforce Hotdrink is produced and marketed by A.
Vogel Bioforce AG of Roggwil, Switzerland. It is not currently sold in the
United States.)
The primary endpoint of the clinical trial was the percentage of patients with
mild or no symptoms after one, five, and 10 days of treatment. At each time
point, the researchers found that a similar number of patients had recovered in
both groups. After day one, 1.5% of patients in the Echinaforce Hotdrink group
and 4.1% of those in the oseltamivir group exhibited mild or no symptoms; recovery
rates for days five and 10 were 50.2% and 48.8%, and 90.1% and 84.8%,
respectively.
Statistical analyses revealed that the two treatments were, in fact,
non-inferior to each other; that is, they were approximately equal in their
therapeutic effects. When the researchers looked at a subgroup of patients with
laboratory-confirmed influenza (as opposed to those with a clinical flu
diagnosis), recovery rates still did not vary between the two actives. Finally,
there was a trend towards a higher proportion of recovered patients after 10
days of treatment with Echinaforce Hotdrink.
“This is yet another significant human clinical trial that helps to document
the clinical benefits of this specific Swiss echinacea extract,” said Mark
Blumenthal, founder and executive director of the American Botanical Council, a
leading nonprofit research and education organization.
“The size of this trial — 473 patients — is one of the largest echinacea
clinical trials ever published,” added Blumenthal, who noted that the largest
echinacea clinical trial in the scientific literature — with 755 subjects — was
conducted with the same Echinaforce extract, and showed a preventive effect
against respiratory tract infections. [2]
“It is rewarding to see an herbal products manufacturer investing
resources in a well-designed clinical study on a phytotherapeutic product,”
noted Stefan Gafner, PhD, ABC’s chief science officer. “The combination of
echinacea and European elderberry has resulted in the same treatment outcome as
the standard drug oseltamivir in the study population, providing evidence for
the safety and efficacy of this product.”
In the new clinical trial, complications were limited in both groups; 6.5% of
patients in the oseltamivir group experienced respiratory-related issues such
as pneumonia, bronchitis, or sinusitis, and gastrointestinal complications. An
insignificantly less number of patients in the Echinaforce group (2.5%)
experienced respiratory, but no gastrointestinal, complications. Researchers
determined that 10 adverse events were related to the treatments — four events
in the Echinaforce group (1.7%) and six events in the oseltamivir group (2.2%),
an insignificant difference. Patients taking oseltamivir were more likely to
experience gastrointestinal issues such as nausea and vomiting.
There were also no statistically significant differences between groups in
terms of antibiotic use, intermediate doctor visits, use of over-the-counter
medications for symptoms, “ability to return to normal daily activities,” or
physician- and patient-reported efficacy of the treatments.
“Echinaforce Hotdrink has here been demonstrated as attractive therapy for
acute influenza treatment with better safety and comparable efficacy profile to
the neuraminidase inhibitor Oseltamivir,” the authors concluded. “Its
availability as over-the-counter medicine allows for a very early treatment
start, which is central for treatment success with any intervention. Further
studies are warranted.”
ABC members and registered users of the ABC website can access the more
detailed ABC HerbClip summary of the study — available here — on ABC’s website (www.herbalgram.org).
References
- Rauš K, Pleschka S, Klein P, Schoop R, Fisher P. Echinaforce
Hotdrink versus oseltamivir in influenza: a randomized, double-blind,
double dummy, multicenter, non-inferiority clinical trial. Curr
Ther Res. 2015; [epub ahead of print]. doi:
10.1016/j.curtheres.2015.04.001.
- Jawad M, Schoop R, Suter A, Klein P, Eccles R. Safety and efficacy
profile of Echinacea purpurea to prevent common cold episodes: a
randomized, double-blind, placebo-controlled trial. Evid
Based Complement Alternat Med. 2012;2012:841315. doi:
10.1155/2012/841315.
|
|
|
|
|
|
|